Phathom Pharmaceuticals to Participate in Upcoming Investor Healthcare Conferences
Phathom Pharmaceuticals (Nasdaq: PHAT) announced participation in several upcoming investor conferences. The Guggenheim Healthcare Talks: 4th Annual Neuro/Immunology Conference will take place on November 14, 2022, at 2:45 PM ET. The Jefferies London Healthcare Conference is scheduled for November 16, 2022, at 9:10 AM BST / 4:10 AM ET. Lastly, the 5th Annual Evercore ISI HealthCONx Conference is set for December 1, 2022, at 1:25 PM ET. Management will hold one-on-one meetings during these events. Webcasts and recordings will be available on Phathom’s website for 90 days post-event.
- None.
- None.
FLORHAM PARK, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, announced today that members of its management team will participate in upcoming investor conferences:
Guggenheim Healthcare Talks: 4th Annual Neuro/Immunology Conference
- Presentation Date: November 14, 2022
- Presentation Time: 2:45 PM ET
Jefferies London Healthcare Conference
- Presentation Date: November 16, 2022
- Presentation Time: 9:10 am BST / 4:10 am ET
5th Annual Evercore ISI HealthCONx Conference
- Presentation Date: December 1, 2022
- Presentation Time: 1:25 PM ET
Company management will also participate in one-on-one meetings throughout the duration of each conference.
To access the live webcast and archived recordings of the presentations, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. The recordings will be available for 90 days following the event.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB). Vonoprazan-based regimens are approved in the U.S. as part of a co-packaged product in combination with antibiotics for the treatment of H. pylori infection in adults, marketed as VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin). Phathom has a New Drug Application under review by the FDA for vonoprazan in erosive esophagitis (EE) and is studying the use of vonoprazan for the treatment of non-erosive reflux disease (NERD). For more information about Phathom, visit the Company’s website at www.phathompharma.com and follow the Company on LinkedIn and Twitter.
MEDIA AND INVESTOR CONTACT:
Nick Benedetto
1-877-742-8466
media@phathompharma.com
ir@phathompharma.com
© 2022 Phathom Pharmaceuticals. All rights reserved.
VOQUEZNA, VOQUEZNA TRIPLE PAK, VOQUEZNA DUAL PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks or trademarks of Phathom Pharmaceuticals, Inc.
FAQ
When is Phathom Pharmaceuticals participating in the Guggenheim Healthcare Talks?
What is the schedule for the Jefferies London Healthcare Conference for Phathom Pharmaceuticals?
When will the 5th Annual Evercore ISI HealthCONx Conference take place for Phathom Pharmaceuticals?
Will Phathom Pharmaceuticals hold one-on-one meetings during these conferences?
Where can I access the live webcasts of Phathom Pharmaceuticals' conference presentations?
